122 related articles for article (PubMed ID: 27068947)
21. Chimeric antigen receptor T-cell therapy for solid tumors.
Newick K; Moon E; Albelda SM
Mol Ther Oncolytics; 2016; 3():16006. PubMed ID: 27162934
[TBL] [Abstract][Full Text] [Related]
22. A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.
Yong CS; John LB; Devaud C; Prince MH; Johnstone RW; Trapani JA; Darcy PK; Kershaw MH
Oncotarget; 2016 Jun; 7(23):34582-98. PubMed ID: 27153556
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells.
Otáhal P; Průková D; Král V; Fabry M; Vočková P; Latečková L; Trněný M; Klener P
Oncoimmunology; 2016 Apr; 5(4):e1115940. PubMed ID: 27141398
[TBL] [Abstract][Full Text] [Related]
24. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
25. Biology and clinical application of CAR T cells for B cell malignancies.
Davila ML; Sadelain M
Int J Hematol; 2016 Jul; 104(1):6-17. PubMed ID: 27262700
[TBL] [Abstract][Full Text] [Related]
26. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer.
Jin C; Fotaki G; Ramachandran M; Nilsson B; Essand M; Yu D
EMBO Mol Med; 2016 Jul; 8(7):702-11. PubMed ID: 27189167
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
[TBL] [Abstract][Full Text] [Related]
28. Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies.
Gill S
Curr Hematol Malig Rep; 2016 Aug; 11(4):318-25. PubMed ID: 27136938
[TBL] [Abstract][Full Text] [Related]
29. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.
Teachey DT; Lacey SF; Shaw PA; Melenhorst JJ; Maude SL; Frey N; Pequignot E; Gonzalez VE; Chen F; Finklestein J; Barrett DM; Weiss SL; Fitzgerald JC; Berg RA; Aplenc R; Callahan C; Rheingold SR; Zheng Z; Rose-John S; White JC; Nazimuddin F; Wertheim G; Levine BL; June CH; Porter DL; Grupp SA
Cancer Discov; 2016 Jun; 6(6):664-79. PubMed ID: 27076371
[TBL] [Abstract][Full Text] [Related]
30. Strategies to genetically engineer T cells for cancer immunotherapy.
Spear TT; Nagato K; Nishimura MI
Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
[TBL] [Abstract][Full Text] [Related]
31. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.
Park JH; Geyer MB; Brentjens RJ
Blood; 2016 Jun; 127(26):3312-20. PubMed ID: 27207800
[TBL] [Abstract][Full Text] [Related]
32. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.
Tian G; Courtney AN; Jena B; Heczey A; Liu D; Marinova E; Guo L; Xu X; Torikai H; Mo Q; Dotti G; Cooper LJ; Metelitsa LS
J Clin Invest; 2016 Jun; 126(6):2341-55. PubMed ID: 27183388
[TBL] [Abstract][Full Text] [Related]
33. Armed T cells with CAR for cancer immunotherapy.
Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
[No Abstract] [Full Text] [Related]
34. 'Off-the-shelf' allogeneic CAR T cells: development and challenges.
Depil S; Duchateau P; Grupp SA; Mufti G; Poirot L
Nat Rev Drug Discov; 2020 Mar; 19(3):185-199. PubMed ID: 31900462
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
36. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
37. Actin cytoskeleton remodeling at the cancer cell side of the immunological synapse: good, bad, or both?
Ockfen E; Filali L; Pereira Fernandes D; Hoffmann C; Thomas C
Front Immunol; 2023; 14():1276602. PubMed ID: 37869010
[TBL] [Abstract][Full Text] [Related]
38. Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy.
Carrasco-Padilla C; Hernaiz-Esteban A; Álvarez-Vallina L; Aguilar-Sopeña O; Roda-Navarro P
Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678761
[TBL] [Abstract][Full Text] [Related]
39. Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges.
Al-Hujaily EM; Al-Sowayan BS; Alyousef Z; Uddin S; Alammari F
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430176
[TBL] [Abstract][Full Text] [Related]
40. Targeting the Tumor Microenvironment in Acute Myeloid Leukemia: The Future of Immunotherapy and Natural Products.
Hino C; Pham B; Park D; Yang C; Nguyen MHK; Kaur S; Reeves ME; Xu Y; Nishino K; Pu L; Kwon SM; Zhong JF; Zhang KK; Xie L; Chong EG; Chen CS; Nguyen V; Castillo DR; Cao H
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
